Moderna has been working closely with the National Institutes of Health since January to find a vaccine, including testing the vaccine on mice before moving on to human trials in March.
Massachusetts-based biotech company Moderna, one of the first drug companies to begin human trials for a COVID-19 vaccine, announced Monday that all the 45 patients who took part in the trials developed COVID-19 antibodies, fuelling enthusiasm that a safe and effective vaccine could soon be available.
Engineers in China work on an experimental vaccine for the COVID-19 coronavirus at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. U.S.-based Moderna announced successful phase one clinical trials for a COVID-19 vaccine, fueling hope that a vaccine maybe available by 2021.
A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus vaccine trials with 600 participants.Moderna has been working closely with the National Institutes of Health since January to find a vaccine and tested the vaccine on mice before moving on to human trials in March.
Earlier this month Moderna announced that the Food and Drug Administration approved Moderna's request for phase two trials and fast track designation of the vaccine.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna coronavirus vaccine releases first human trial results - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Read more »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Read more »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Read more »
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine.
Read more »
Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says | Markets InsiderGoldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed 'encouragi...
Read more »
Stocks making the biggest moves midday: Moderna, Delta, Bank of America, Best Buy, Disney & moreModerna shares spike on 'positive data' from its coronavirus vaccine trial. Netflix shares slip as investors rotate out of 'stay-at-home' stocks.
Read more »